These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1041 related items for PubMed ID: 32854838

  • 1. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
    Ambrosy AP, Braunwald E, Morrow DA, DeVore AD, McCague K, Meng X, Duffy CI, Rocha R, Velazquez EJ, PIONEER-HF Investigators.
    J Am Coll Cardiol; 2020 Sep 01; 76(9):1034-1048. PubMed ID: 32854838
    [Abstract] [Full Text] [Related]

  • 2. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators.
    JAMA Cardiol; 2020 Feb 01; 5(2):202-207. PubMed ID: 31825471
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators.
    N Engl J Med; 2019 Feb 07; 380(6):539-548. PubMed ID: 30415601
    [Abstract] [Full Text] [Related]

  • 4. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure.
    Morrow DA, Velazquez EJ, Desai AS, DeVore AD, Lepage S, Park JG, Sharma K, Solomon SD, Starling RC, Ward JH, Williamson KM, Zieroth S, Hernandez AF, Mentz RJ, Braunwald E.
    J Am Coll Cardiol; 2024 Mar 26; 83(12):1123-1132. PubMed ID: 38508844
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin-Neprilysin Inhibition in Black Americans: Data From the PIONEER-HF Trial.
    Berardi C, Braunwald E, Morrow DA, Mulder HS, Duffy CI, O'Brien TX, Ambrosy AP, Chakraborty H, Velazquez EJ, DeVore AD, PIONEER-HF Investigators.
    JACC Heart Fail; 2020 Oct 26; 8(10):859-866. PubMed ID: 32919915
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial.
    Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA, Braunwald E.
    Am Heart J; 2018 Apr 26; 198():145-151. PubMed ID: 29653636
    [Abstract] [Full Text] [Related]

  • 7. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV.
    Eur Heart J; 2017 Apr 14; 38(15):1132-1143. PubMed ID: 28158398
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
    Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD.
    Circ Heart Fail; 2021 Feb 14; 14(2):e007034. PubMed ID: 33530704
    [Abstract] [Full Text] [Related]

  • 9. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM.
    J Am Heart Assoc; 2021 Feb 16; 10(4):e019238. PubMed ID: 33522249
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA.
    JACC Heart Fail; 2020 Oct 16; 8(10):834-843. PubMed ID: 32800511
    [Abstract] [Full Text] [Related]

  • 11. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ.
    Circ Heart Fail; 2016 Mar 16; 9(3):e002744. PubMed ID: 26915374
    [Abstract] [Full Text] [Related]

  • 12. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
    Shi V, Senni M, Streefkerk H, Modgill V, Zhou W, Kaplan A.
    Int J Cardiol; 2018 Aug 01; 264():118-123. PubMed ID: 29776559
    [Abstract] [Full Text] [Related]

  • 13. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM.
    JACC Heart Fail; 2020 Jan 01; 8(1):43-54. PubMed ID: 31838035
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV.
    JACC Heart Fail; 2017 Jul 01; 5(7):471-482. PubMed ID: 28662936
    [Abstract] [Full Text] [Related]

  • 15. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF.
    Mogensen UM, Køber L, Kristensen SL, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV, PARADIGM-HF Investigators and Committees.
    Am Heart J; 2017 Jun 01; 188():35-41. PubMed ID: 28577679
    [Abstract] [Full Text] [Related]

  • 16. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK, Claggett BL, Solomon SD, McMurray JJV, Packer M, Zile MR, Desai AS, Rouleau JL, Swedberg K, Fonarow GC.
    JAMA Cardiol; 2018 Dec 01; 3(12):1226-1231. PubMed ID: 30484837
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS, McMurray JJ.
    Heart; 2016 Sep 01; 102(17):1342-7. PubMed ID: 27207980
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.